Novo Nordisk on Wednesday said its net profit came in at 20.05 billion Danish kroner in the second quarter of 2024, below forecasts.
EBIT — earnings before interest and tax — came in at 25.93 billion Danish kroner in the second quarter, which was also below the LSEG forecast of 26.86 billion Danish kroner.saying growth was now anticipated to come in between 20% and 28%, rather than the previously expected 22% to 30% range. Sales of popular weight loss drug Wegovy jumped 55% in the second quarter of 2024, compared to the same period in 2023, coming in at 11.66 billion kroner.
ایران آخرین اخبار, ایران سرفصلها
Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.
منبع: NBCLA - 🏆 319. / 59 ادامه مطلب »
منبع: CNBC - 🏆 12. / 72 ادامه مطلب »
منبع: NBCNewYork - 🏆 270. / 63 ادامه مطلب »
منبع: CNBC - 🏆 12. / 72 ادامه مطلب »